Effect of Hypoxic Exposure on Blood Variables in Elite Wrestlers

January 15, 2025 updated by: Poznan University of Physical Education

The Influence of Sports and Hypoxic Training on the Regeneration and Adaptation of Skeletal Muscles to Exercise in Wrestlers.

Twelve male wrestlers of the National Polish Team were observed in the study during the camp. The hypoxia group (n=6) participated in sports training and hypoxic exposure, while the control group (n=6) included wrestlers participating only in sports training. The hypoxic group lived and slept in hypoxic rooms. During the camp, all wrestlers followed the same training schedule and diet. In the blood were determined levels of creatine kinase (CK), C-reactive protein (hsCRP) concentration, nitric oxide (NO), morphology, reticulocytes, lipid profile, and ferritin. Also vascular endothelial growth factor (VEGF, VEGFR2, and VEGFR3), erythropoietin (EPO), angiopoietin (Ang 1, Ang 2), endothelial cell adhesion factor-1 (VCAM-1), Erythropoietin (EPO) and hypoxia-inducible factor 1 (HIF-1). Body weight composition was determined.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hypoxia exposure applied to professional athletes has attracted attention and scientific debate due to its effects on improving physiological response through cardiovascular and hematological mechanisms. Presently, hypoxic training programs are developed to improve exercise performance in athletes, a useful training method for athletes that may improve their performance in future sea-level competitions. 12 males were divided into the hypoxic (H) and control (C) groups. Group H was living and sleeping in hypoxic rooms (method live high-train low) for 8-14h/d (FiO2≈14%). The implementation of the project was intended to: 1) assess the dynamics of changes in the concentration of pro-inflammatory indicators and hematopoiesis in athletes to variable training loads and hypoxia, 2) explain the usefulness of hypoxic exposure in adaptation to physical exercise, 3) observe the length of the hypoxic cycle necessary to maintain the effect of high-altitude training. In the blood serum the level of basic biochemical indicators of fatigue related to muscle damage, inflammation, and energy deficit, i.e. total creatine kinase (CK) activity, C-reactive protein (hsCRP) concentration, nitric oxide (NO). Moreover, basic hematological indicators: morphology, reticulocytes, lipid profile, and ferritin. Also, angiogenesis regulators: vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR2 and VEGFR3), erythropoietin (EPO), angiopoietin (Ang 1, Ang 2), endothelial cell adhesion factor-1 (VCAM-1), Erythropoietin (EPO) and hypoxia-inducible factor 1 (HIF-1). Body weight composition was determined using a body analyzer. Further investigations into hypoxia methods while considering individual capabilities are necessary for gaining deeper insights, into how hypoxia affects blood count and different blood variables among athletes.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • member of national wrestler's teams, and sports camp participant.

Exclusion Criteria:

  • negative symptoms of hypoxia, and/or injury.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hypoxia
Live High-Train Low method was used.
The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
No Intervention: Control group
The control group was participating in the same training protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CK
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
creatine kinase
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
hsCRP
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
reactive C-protein
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
HIF-1
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
hypoxia-inducible factor 1
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
EPO
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
Erythropoietin
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
VEGF, VEGF 2, VEGF 3.
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
vascular endothelial growth factor
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
Ang 1, Ang 2
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
angiopoietin
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
VCAM-1
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
endothelial cell adhesion factor-1
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood count
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
morphology
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
lipid profile
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
HDL, LDL, triglycerides
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
ferritin
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
ferritin
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
Time Frame: The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.
nitric oxide
The blood was taken at the beginning of the camp (baseline), after 6 days, after 15 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anna Kasperska, Poznań University of Physical Education, Faculty of Sport Sciences in Gorzów Wielkopolski, Poland;

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 2, 2013

Primary Completion (Actual)

December 18, 2013

Study Completion (Actual)

December 18, 2013

Study Registration Dates

First Submitted

April 12, 2024

First Submitted That Met QC Criteria

April 17, 2024

First Posted (Actual)

April 18, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 15, 2025

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Wrestlers LH-TL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypoxia

Clinical Trials on hypoxia

Subscribe